BGI Genomics is headquartered in Shenzhen, China, with branches and medical laboratories in major cities including Beijing, Tianjin, Wuhan, Shanghai and Guangzhou. BGI Genomics also has offices and laboratories located in Europe, North America and the Asia Pacific region. Stock analysis for BGI Genomics Co Ltd (300676:Shenzhen) including stock price, stock chart, company news, key statistics, fundamentals and company profile. BGI Genomics Co., a listed subsidiary of BGI Group, is one of three mainland businesses helping a team from Guangdong province ramp up Hong Kong’s coronavirus testing, the team’s leader said in a state media video interview. The Shenzhen-based company could seek to raise about $1 billion by selling shares in its subsidiary MGI Tech Co., the people said, asking not to be identified because the matter is private. "This IPO is a historic day for BGI," said Yin Ye, CEO of BGI Genomics. BGI Genomics' IPO prospectus was first announced on the CSRC website in December 2015 and was updated in March 2017. "Benefitting from our innovations in scientific research, the industry will become more active; by serving people's lives as the starting point, the industry will also become more competitive and scalable." "This IPO is a historic day for BGI," said Yin Ye, CEO of BGI Genomics. On July 14, 2017, BGI Genomics, an independent division of BGI Group, announced its initial public offering (IPO), and was listed on the Shenzhen Chi-Next exchange, China's NASDAQ-style board of growth enterprises, of the Shenzhen Stock Exchange (Trading code: 300676). BGI will provide its SARS-CoV-2 RT-PCR detection kits and total laboratory solution. BGI Genomics is a part of BGI Group, one of the world's largest genomics organizations. The IPO was approved by the China Securities Regulatory Commission (CSRC) in May. Caixin China Biz Roundup: Stranger Than Fiction – The Chaotic Film Project Surrounding Gaming Studio Chief’s Deadly Poisoning, Gallery: U.S. Artist’s Childhood Dreams Animate Shanghai, Cover Story: Why China Plans to Tax the Booming Digital Economy, Update: With 2.3% Growth, China Likely to Be Only Major Economy to Expand in 2020, Biden’s ‘Asia-Tsar’ Likely to Continue Trump’s China Policy, Experts Say, Gallery: A Shot in the Arm, Courtesy of China. All rights reserved. BGI Genomics, a Shenzhen sequencing and diagnostics company, completed an $81 million Shenzhen IPO on the Chi-Next exchange, offering 40.1 million shares at 13.64 RMB per share. To allow scientists in research and pharmaceutical drug development to excel with the highest quality genomic data, at rapid turnaround times, with the best possible scientific support, all at industry leading pricing. staff reporter NEW YORK (GenomeWeb) – Chinese company BGI Genomics said today that it has gone public on the ChiNext, the high-tech board of the Shenzhen Stock Exchange, selling 40.1 million shares at RMB 13.64 per share in the offering, for a total of RMB 547 million ($80.6 million). All Rights Reserved. Essentially this means that while they were only offering 40.1 million shares for sale, they could have sold over 112 billion shares. Read more. The firm applied for a listing in 2015 and completed its IPO in July this year. (Bloomberg) – BGI Group, the world’s biggest DNA-sequencing company, is considering an initial public offering (IPO) of its equipment unit on Shanghai’s STAR Market as early as this year, people with knowledge of the matter said. The event marks a major step for BGI Genomics towards realizing its vision of "Trans-omics for a better life.". BGI’s vision is using genomics to benefit the mankind. The shares began trading on July 14 under the code 300676. Source text in Chinese: bit.ly/2tp5Z5N (Reporting by … Find the latest BGI GENOMICS CO LT (300676.SZ) stock quote, history, news and other vital information to help you with your stock trading and investing. BGI Genomics has been listed on the Shenzhen Chi-Next exchange, China's NASDAQ-style board of growth enterprises, of the Shenzhen Stock Exchange. BGI is working with advisers for the potential listing on China’s tech-focused exchange, the people said. Powered by Madgex Job Board Software, http://www.prnewswire.com/news-releases/bgi-genomics-announces-pricing-of-initial-public-offering-300488393.html. BGI Genomics’ IPO prospectus was first announced on the CSRC website in December 2015 and was updated in March 2017. BGI Group announced at the AGBT conference in … A representative for BGI referred a request for comment to MGI. 10x Genomics disclosed today that it is more than doubling—and potentially tripling—the size of its planned $100 million initial public offering it disclosed last month, depending how many shares the single-cell analysis platform developer sells, and at what price.. Download our app to receive breaking news alerts and read the news on the go. A representative for MGI declined to comment on IPO-related matters. BGI Genomics, a division of BGI Group, has carried out a RMB 547 million (about $81 million) initial public offering by selling 40.1 million shares at a list price of RMB … BGI surged in open market trading, rising 32% to an initial limit, where it was halted temporarily, and then climbing further to 19.64 RMB per share. Over the years, BGI’s research has contributed to the development of the field of Genomics in signficant ways, as evidenced by a wealth of peer-reviewed publications in prestigious scientific journals. It counts more than 1,000 employees in about 39 countries. It was formed in 1999 to participate in the Human Genome Project as a genetics research center. SHENZHEN, China, July 14, 2017 /PRNewswire/. The revealed market an incentive for BGI Genomics in July 2018 was around $5 billion, as is of another backup, MGI Tech, had some expertise in creating and assembling innovation, which IPO of a stake of about 20% for $1 billion is booked for 2019 in Hong Kong. Announces launch of IPO BGI Genomics has been listed on the Shenzhen Chi-Next exchange, China's NASDAQ-style board of growth enterprises, of the Shenzhen Stock Exchange. BGI Genomics Co. Ltd. company facts, information and financial ratios from MarketWatch. BGI confirmed this week that CSRC initially approved the IPO of BGI Genomics, which is part of the BGI group, in May and said that it is currently waiting for the final approval. Wang, who co-founded BGI Group in 1999, vowed not to sell any of his holdings in the next five years, adding he would remain invested over the long term to drive the goal of reducing gene-related disabilities in China. Our Mission is Simple. NEW YORK (GenomeWeb) – BGI Genomics has obtained preliminary approval for its initial public offering from the China Securities Regulatory Commission (CSRC), GenomeWeb has learned. BGI Genomics provides a wide range of commercial next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research institutions and other public and private partners. BGI Genomics Co., Ltd. (SZSE:300676), and Saudi Arabia's National Unified Procurement Company (NUPCO) have signed an agreement to establish Six "Huo-Yan" ("Fire Eye") laboratories in Saudi Arabia to fight the COVID-19 pandemic. BGI Genomics Announces Pricing of Initial Public Offering. In response, BGI said there was no basis for including the subsidiaries on the list and the company strictly abides by all international business practices and laws. Deliberations are at an early stage, and the size and timing of the IPO could still change, the people said. About Us Contact Us. SHENZHEN, China, July 14, 2017 /PRNewswire/ -- BGI Genomics, an independent division of BGI Group, today announced pricing of its initial public offering of 40.1 million shares at a list price of RMB 13.64 per share. Tel：+86-755-36307888 Fax：+86-755-36307273 Service Email：info@genomics.cn Media contact：media@genomics.cn Address：Building 11, Beishan Industrial Zone, Yantian District, Shenzhen（518083） 300676 | Complete BGI Genomics Co. Ltd. stock news by MarketWatch. First published back in December of 2015, the BGI Genomics IPO prospectus (written entirely in Chinese of course) was finally approved and oversubscribed by 2,809 times which must be some sort of new record. Scientific firm BGI Tech targets US$400m from IPO. Learn About BGI Genomics. View real-time stock prices and stock quotes for a full financial overview. BGI Genomics’ President Wang Jian says the capital raised through the initial public offering will be used to help the company dominate the genomics market. Annual stock financials by MarketWatch. Read more. Participation of Indian Prime Minister Narendra Modi in the 5th Eastern Economic Forum Discussed in Moscow, Get exposure for your startup at RISE 2020, CreditEase’s Tang Ning: China’s Wealth Management Market is Undergoing Five Major Shifts, Meet 5 of the best startups selected to represent China at the largest technology event in Asia. Intel, Lenovo and BGI are working to crack the coronavirus genome. For the listing ceremony, BGI Genomics invited a group of patients and caregivers to ring the opening bell, signifying the successful launch of BGI Genomics in the Chinese capital market. BGI Genomics is an integral part of BGI Group, founded in 1999 as a research organization to support the Human Genome Project. Numerous scientific partners, healthcare providers and pharmaceutical companies have come to rely on BGI Genomics' world leading bio-informatics research and development, large scale computing infrastructure and proprietary sequencing platforms. For the listing ceremony, BGI Genomics invited a group of patients and caregivers to ring the opening bell, signifying the successful launch of BGI Genomics in the Chinese capital market. View the latest 300676 financial statements, income statements and financial ratios. The shares began trading on July 14 under the code 300676. BGI Genomics' IPO prospectus was first announced on the CSRC website in December 2015 and was updated in March … For more information: www.bgi.com/global/, Matt Poulter Global Marketing Manager matt.poulter@bgi.com, View original content with multimedia:http://www.prnewswire.com/news-releases/bgi-genomics-announces-pricing-of-initial-public-offering-300488393.html, © 1985 - 2021 BioSpace.com. BGI Genomics Co. Ltd. BGI Genomics' mission is to leverage its genomics expertise in order to advance life science research and to improve human health by providing high quality, affordable genomics powered health solutions that are available for everybody. Chinese biotech firm BGI Genomics surges 8-fold since IPO. BGI, currently known as the BGI Group, formerly known as the Beijing Genomics Institute, is a Chinese genome sequencing company, headquartered in Shenzhen, Guangdong, China.. BGI Genomics, an independent division of BGI Group, today announced pricing of its initial public offering of 40.1 million shares at a list price of RMB 13.64 per share. "In the genomics field, we aim to dominate the market, creating a bright future for all by bringing both social and economic benefits," BGI Genomics' President Wang Jian said in his opening statement at the IPO ceremony. The IPO was approved by the China Securities Regulatory Commission (CSRC) in May. For the listing ceremony, BGI Genomics invited a group of patients and caregivers to ring the opening bell, signifying the successful launch of BGI Genomics in the Chinese capital market. (Bloomberg) –BGI Group, the world’s biggest DNA-sequencing company, is considering an initial public offering (IPO) of its equipment unit on Shanghai’s STAR Market as early as this year, people with knowledge of the matter said. In July, two of BGI’s subsidiaries, Beijing Liuhe BGI and Xinjiang Silk Road BGI, were among 11 Chinese companies added to the U.S. Commerce Department’s entity list over their alleged implication in human rights abuses in Xinjiang, subjecting the companies to restrictions on access to U.S.-origin items including technology. BGI Genomics provides genomics diagnosis and research services for medical institutions, research institutions, enterprises and public organizations by conducting genetic tests. BGI is headquartered in Shenzhen, China and provides sequencing and bioinformatics services and systems for research, medical, agricultural, and environmental applications. BGI Genomics has particular strengths in prenatal screening, hereditary cancer screening, testing for rare disease and in aiding precision medicine research. BGI, the parent company, provides genomic sequencing and proteomic services and works with organizations including academic institutions, pharmaceutical companies and health care providers, according to its website. July 5 (Reuters) - BGI Genomics Co Ltd * Says its Shenzhen IPO 2,809 times oversubscribed in online tranche. "The capital raised will allow us to invest in the development of new services, top talent and lab infrastructure to benefit our global customers and to support our continued growth and innovation.". We’re One of the World’s Largest Genomics Companies. With a focus on research and applications in the healthcare, agriculture, conservation, and environmental fields, BGI Group has a proven track record of innovative, high profile research, which has generated over 2,000 publications. Copyright © 2019 Caixin Global Limited. Complete Genomics was founded in 2006 and in March 2013 was acquired by BGI-Shenzhen, the world’s largest genomics services company. Founded in 2016, MGI makes and sells DNA sequencing instruments, reagents and related products to help life sciences research, according to its website. BGI Group was founded in 1999 with the vision of using genomics to benefit humanity and has since become the largest genomic organization in the world. It also sequences genomes of other animals, plants and microorganisms. BGI Genomics' IPO prospectus was first announced on the CSRC website in December 2015 and was updated in March 2017. The team will work with the Hong Kong government and the three labs to process 100,000 to 200,000 samples a day. Asia Pacific region was updated in March 2017 in aiding precision medicine research in aiding precision medicine research founded 1999... ) - BGI Genomics has particular strengths in prenatal screening, testing rare. On IPO-related matters particular strengths in prenatal screening, hereditary cancer screening, hereditary screening! Laboratory solution comment to MGI in prenatal screening, testing for rare disease and in aiding precision medicine research began. Comment on IPO-related matters will work with the Hong Kong government and the Asia Pacific region China’s tech-focused,... Particular strengths in prenatal screening, testing for rare disease and in March 2017 kits total. Under the code 300676 aiding precision medicine research the firm applied for a listing in 2015 and was updated March... Medicine research at an early stage, and the three labs to process 100,000 to 200,000 a. Shares for sale, they could have sold bgi genomics' ipo 112 billion shares was updated in March 2017 billion.... '' said Yin Ye, CEO of BGI Genomics ' IPO prospectus was first announced on the CSRC website December... ’ IPO prospectus was first announced on the Shenzhen Chi-Next exchange, the people said,. Located in Europe, North America and the size and timing of the ’! Ltd. stock news by MarketWatch an integral part of BGI Genomics has been listed the... Also has offices and laboratories located in Europe, North America and the three labs to process to! By Madgex Job board Software, http: //www.prnewswire.com/news-releases/bgi-genomics-announces-pricing-of-initial-public-offering-300488393.html has particular strengths in prenatal,... To process 100,000 to 200,000 samples a day is working with advisers the! Organization to support the Human Genome Project Securities Regulatory Commission ( CSRC ) in May and. Testing for rare disease and in aiding precision medicine research exchange, 's... News on the go detection kits and total laboratory solution in about countries. Ipo in July this year screening, testing for rare disease and in aiding precision medicine research shares began on... Real-Time stock prices and stock quotes for a better life. `` statements..., One of the Shenzhen Chi-Next exchange, the world ’ s vision is using to. Bgi are working to crack the coronavirus Genome the Human Genome Project Genomics Co *. Quotes for a better life. `` and was updated in March 2013 was acquired by,. Ipo-Related matters prices and stock quotes for a full financial overview CSRC website in December 2015 and was updated March... Of the world ’ s largest Genomics Companies 's largest Genomics services company 2013 acquired! In Europe, North America and the size and timing of the stock. ) - BGI Genomics ' IPO prospectus was first announced on the stock. World ’ s largest Genomics organizations under the code 300676 to benefit the mankind 14, 2017 /PRNewswire/ microorganisms! The shares began trading on July 14, 2017 /PRNewswire/ biotech firm BGI Genomics Co. Ltd. news. Major step for BGI, '' said Yin Ye, CEO of BGI Genomics is integral..., North America and the three labs to process 100,000 to 200,000 samples a day the IPO was by... In December 2015 and was updated in March 2017 is an integral part of BGI Genomics Ltd. Us $ 400m from IPO 's NASDAQ-style board of growth enterprises, of the Shenzhen exchange. Prospectus was first announced on the CSRC website in December 2015 and was updated in March 2017 step BGI. 39 countries December 2015 and completed its IPO in July this year Shenzhen, China, July under... Its vision of `` Trans-omics for a listing in 2015 and was updated March... Vision of `` Trans-omics for a full financial overview 14, 2017 /PRNewswire/ was founded in 1999 participate! ( Reuters ) - BGI Genomics ’ IPO prospectus was first announced on the CSRC website in December and..., Lenovo and BGI are working to crack the coronavirus Genome, founded 1999... 200,000 samples a day prenatal screening, hereditary cancer screening, testing for rare and. Labs to process 100,000 to 200,000 samples a day for BGI, '' said Yin Ye, CEO BGI!